[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334776-105":59,"doc-detail-334776-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evaluating-the-utility-of-znf331-promoter-methylation-as-a-prognostic-and-predictive-marker-in-stage-iii-colon-cancer-results-from-calgb-89803-alliance","Evaluating the utility of ZNF331 promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance)","","Epigenomic alterations are common in colorectal cancers, yet few epigenomic biomarkers effectively risk-stratify patients. This study evaluates whether ZNF331 promoter hypermethylation (mZNF331) functions as a prognostic and predictive marker in stage III colon cancer. Using bisulphite conversion and fluorescence-based real-time PCR, investigators analyzed methylation status, clinicopathologic features, relapse, survival, and treatment efficacy in 385 patients from CALGB/Alliance 89803. mZNF331 was present in 69.4% of cases, with no significant differences in disease-free or overall survival versus unmethylated tumors, including across treatment arms, suggesting limited applicability.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluating-the-utility-of-znf331-promoter-methylation-as-a-prognostic-and-predictive-marker-in-stage-iii-colon-cancer-results-from-calgb-89803-alliance/334776/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluating-the-utility-of-znf331-promoter-methylation-as-a-prognostic-and-predictive-marker-in-stage-iii-colon-cancer-results-from-calgb-89803-alliance/334776.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study?","Question",{"text":112,"@type":113},"To determine whether ZNF331 promoter hypermethylation (mZNF331) can serve as a prognostic and predictive biomarker in stage III colon cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was ZNF331 promoter methylation measured?",{"text":117,"@type":113},"ZNF331 promoter methylation status was determined by bisulphite conversion and fluorescence-based real-time polymerase chain reaction.",{"name":119,"@type":110,"acceptedAnswer":120},"Did mZNF331 improve prognosis or predict treatment outcomes?",{"text":121,"@type":113},"No. There was no significant difference in disease-free or overall survival between mZNF331 and unmethylated ZNF331 tumors, including when analyses were stratified by treatment arms.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334776,1790795145,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","RESEARCH ARTICLE     \nEvaluating the utility of ZNF331 promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance)  \nElizabeth S. Nakasonea,b, Tyler J. Zemlac, Ming Yub, She Yu Linb,d, Fang-Shu Ouc, Kelly Carterb, Federico Innocentie, Leonard Saltzf, William M. Gradyb,g, and Stacey A. Cohen a,b  \naDivision of Oncology, University of Washington, Seattle, WA, USA; bTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; cAlliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA; dSchool of Life Sciences, Nantong University, Nantong, P.R. China; e Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; fDepartment of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; gDivision of Gastroenterology, University of Washington, Seattle, WA, USA  \nABSTRACT  \nWhile epigenomic alterations are common in colorectal cancers (CRC), few epigenomic biomarkers that risk-stratify patients have been identified. We thus sought to determine the potential of ZNF331 promoter hypermethylation (mZNF331) as a prognostic and predictive marker in colon cancer. We examined the association of mZNF331 with clinicopathologic features, relapse, survival, and treatment efficacy in patients with stage III colon cancer treated within a randomized adjuvant chemotherapy trial (CALGB/Alliance89803). Residual tumour tissue was available for genomic DNA extraction and methylation analysis for 385 patients. ZNF331 promoter methylation status was determined by bisulphite conversion and fluorescence-based real-time polymerase chain reaction. Kaplan-Meier estimator and Cox proportional hazard models were used to assess the prognostic and predictive role of mZNF331 in this well-annotated dataset, adjusting for clinicopathologic features and standard molecular markers. mZNF331 was observed in 267/385 (69.4%) evaluable cases. Histopathologic features were largely similar between patients with mZNF331 compared to unmethylated ZNF331 (unmZNFF31). There was no significant difference in disease-free or overall survival between patients with mZNF331 versus unmZNF331 colon cancers, even when adjusting for clinicopathologic features and molecular marker status. Similarly, there was no difference in disease-free or overall survival across treatment arms when stratified by ZNF331 methylation status. While ZNF331 promoter hypermethylation is frequently observed in CRC, our current study of a small subset of patients with stage III colon cancer suggests limited applicability as a prognostic marker. Larger studies may provide more insight and clarity into the applicability of mZNF331 as a prognostic and predictive marker.  \nARTICLE HISTORY  \nReceived 20 September 2023  \nRevised 6 March 2024 Accepted 23 April 2024  \nKEYWORDS  \nCALGB 89803 (Alliance); epigenetic factors; DNA methylation; ZNF331; biomarker; stage III colon cancer  \nIntroduction  \nColorectal cancer (CRC) is a group of heterogeneous diseases that arise from the gradual accumulation of genetic and epigenetic alterations [ 1]. A major driver of carcinogenesis is the development of specific molecular phenotypes that give rise to genomic instability, most commonly through chromosomal instability (CIN) or microsatellite instability (MSI). CIN results in chromosomal gains, losses, and translocations. MSI arises from disruptions in DNA mismatch repair (MMR) mechanisms, leading to the progressive accumulation of gain- and loss-of-function mutations [2,3].  \nIn addition to genomic instability, aberrant epigenomic alterations are also frequently observed in  \nCRC, typically through covalent histone modification and DNA methylation [4–6], affecting transcription without altering the underlying genomic sequence. These transmissible alterations have been increasingly identified as contributors to both CRC carci","cbCaijbVsNhowXFT","https://ap.wps.com/l/cbCaijbVsNhowXFT","pdf",1846903,14,"English","# Abstract\n# Introduction\n## Genetic and epigenomic drivers in colorectal cancer","[{\"question\":\"What is the main goal of the study?\",\"answer\":\"To determine whether ZNF331 promoter hypermethylation (mZNF331) can serve as a prognostic and predictive biomarker in stage III colon cancer.\"},{\"question\":\"How was ZNF331 promoter methylation measured?\",\"answer\":\"ZNF331 promoter methylation status was determined by bisulphite conversion and fluorescence-based real-time polymerase chain reaction.\"},{\"question\":\"Did mZNF331 improve prognosis or predict treatment outcomes?\",\"answer\":\"No. There was no significant difference in disease-free or overall survival between mZNF331 and unmethylated ZNF331 tumors, including when analyses were stratified by treatment arms.\"}]","Evaluating the utility of ZNF331 promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance) | PDF",1790008347,35]